Drug discovery beyond the rule of 5 - Opportunities and challenges
B.C. Doak, Jan O. Kihlberg · Expert Opinion on Drug Discovery · 2016
Targets that are ‘difficult-to-drug’ typically have binding sites that are large, highly lipophilic or polar, flexible, flat or featureless [1]. They contain few opportunities for high affinity int...